ATE533762T1 - Chinolin- oder isochinolinsubstituierte p2x7- antagonisten - Google Patents

Chinolin- oder isochinolinsubstituierte p2x7- antagonisten

Info

Publication number: ATE533762T1
Authority: AT; Austria
Prior art keywords: quinoline; antagonists; compounds; isoquinoline substituted; isoquinoline
Prior art date: 2008-04-22

Application number

AT09735472T

Other languages

English (en)

Inventor

Christopher Love

Joseph Leenaerts

Ludwig Cooymans

Alec Lebsack

Bryan Branstetter

Jason Rech

Elizabeth Gleason

Jennifer Venable

Danielle Wiener

Deborah Smith

James Breitenbucher

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-22

Filing date

2009-04-21

Publication date

2011-12-15

2009-04-21 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE533762T1 publication Critical patent/ATE533762T1/de

Links

102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 3
101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 3
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical group C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
239000005557 antagonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
241001465754 Metazoa Species 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
238000001311 chemical methods and process Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT09735472T 2008-04-22 2009-04-21 Chinolin- oder isochinolinsubstituierte p2x7- antagonisten ATE533762T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08154909		2008-04-22
PCT/US2009/041249 WO2009132000A1 (en)	2008-04-22	2009-04-21	Quinoline or isoquinoline substituted p2x7 antagonists

Publications (1)

Publication Number	Publication Date
ATE533762T1 true ATE533762T1 (de)	2011-12-15

Family

ID=39462005

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09735472T ATE533762T1 (de)	2008-04-22	2009-04-21	Chinolin- oder isochinolinsubstituierte p2x7- antagonisten

Country Status (10)

Country	Link
US (1)	US8431704B2 (de)
EP (1)	EP2285800B1 (de)
JP (1)	JP5369173B2 (de)
KR (1)	KR101598397B1 (de)
CN (1)	CN102066360B (de)
AT (1)	ATE533762T1 (de)
AU (1)	AU2009239471B2 (de)
CA (1)	CA2722035C (de)
ES (1)	ES2376092T3 (de)
WO (1)	WO2009132000A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2542670A2 (de)	2010-03-05	2013-01-09	President and Fellows of Harvard College	Zusammensetzungen aus induzierten dentritischen zellen und ihre verwendung
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
CN103687860B (zh)	2011-07-22	2016-06-08	埃科特莱茵药品有限公司	作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en)	2012-01-20	2016-08-09	Actelion Pharmaceuticals Ltd.	Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2013132253A1 (en)	2012-03-07	2013-09-12	Institute Of Cancer Research: Royal Cancer Hospital (The)	3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
TW201427947A (zh) *	2012-10-12	2014-07-16	Lundbeck & Co As H	環狀胺
TWI598325B (zh) *	2012-10-12	2017-09-11	Ｈ朗德貝克公司	苯甲醯胺類
WO2014091415A1 (en) *	2012-12-12	2014-06-19	Actelion Pharmaceuticals Ltd	Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (ko)	2012-12-18	2021-03-26	이도르시아 파마슈티컬스 리미티드	Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es)	2013-01-22	2017-06-14	Actelion Pharmaceuticals Ltd.	Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (en)	2013-01-22	2022-05-10	Actelion Pharmaceuticals Ltd	Heterocyclic amide derivatives as p2x7 receptor antagonists
US9040534B2 (en)	2013-03-14	2015-05-26	Janssen Pharmaceutica Nv	[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US9604982B2 (en)	2013-03-14	2017-03-28	Janssen Pharmaceutica Nv	P2X7 modulators
TWI644671B (zh)	2013-03-14	2018-12-21	比利時商健生藥品公司	Ｐ２ｘ７調節劑
JO3509B1 (ar)	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
EP3044221B1 (de)	2013-09-11	2018-02-21	Institute of Cancer Research: Royal Cancer Hospital (The)	3-aryl-5-substituierte isochinolin-1-on-verbindungen und deren therapeutische anwendung
EP2905282A1 (de)	2014-02-05	2015-08-12	AXXAM S.p.A.	Substituierte Thiazole oder Oxazole als P2X7-Rezeptorantagonisten
CN106573907B (zh) *	2014-06-05	2020-09-08	默克专利有限公司	喹啉衍生物及其用于神经退化性疾病的用途
WO2016039977A1 (en)	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulators
AU2015315693B2 (en)	2014-09-12	2020-01-16	Janssen Pharmaceutica Nv	P2X7 modulating n-acyl-triazolopyrazines
US9592186B2 (en)	2014-09-30	2017-03-14	Avon Products, Inc.	Topical compositions and methods for skin lightening
EP3290417A1 (de)	2016-08-31	2018-03-07	AXXAM S.p.A.	2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamide und ihre verwendung als p2x7 rezeptor antagonisten
EP3290416A1 (de) *	2016-08-31	2018-03-07	AXXAM S.p.A.	Substituierte n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- und n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- derivate und ihre verwendung als p2x7 rezeptor antagonist
WO2018170203A1 (en)	2017-03-16	2018-09-20	Celgene Car Llc	Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3398941A1 (de)	2017-05-03	2018-11-07	AXXAM S.p.A.	Heterozyklische p2x7-antagonisten
WO2018224455A1 (en)	2017-06-07	2018-12-13	Basf Se	Substituted cyclopropyl derivatives
WO2018234488A1 (en)	2017-06-23	2018-12-27	Basf Se	Substituted cyclopropyl derivatives
WO2019078040A1 (ja) *	2017-10-18	2019-04-25	国立大学法人大阪大学	化合物またはその結合物、及び有機半導体材料
WO2019121143A1 (en)	2017-12-20	2019-06-27	Basf Se	Substituted cyclopropyl derivatives
KR20210069079A (ko)	2018-09-28	2021-06-10	얀센 파마슈티카 엔.브이.	모노아실글리세롤 리파아제 조절제
MY205440A (en)	2018-09-28	2024-10-21	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
WO2020227159A2 (en)	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
JP7697934B2 (ja)	2019-09-30	2025-06-24	ヤンセンファーマシューティカエヌ．ベー．	放射線標識されたｍｇｌｐｅｔリガンド
BR112022019077A2 (pt)	2020-03-26	2022-12-27	Janssen Pharmaceutica Nv	Moduladores da monoacilglicerol lipase
CN111285812A (zh) *	2020-04-08	2020-06-16	安徽昊帆生物有限公司	2-芳氨基-5-甲酰基-嘧啶的制备方法
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4015039A1 (de)	2020-12-18	2022-06-22	AXXAM S.p.A.	Heterocyclische derivate als p2x7-rezeptor-antagonisten
US20240368092A1 (en)	2021-09-03	2024-11-07	Breye Therapeutics Aps	2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists
CN120981228A (zh) *	2022-11-17	2025-11-18	腾维治疗公司	化合物、组合物和方法
CN121843919A (zh)	2023-09-13	2026-04-10	苏文生命科学有限公司	作为p2x7受体拮抗剂的n-芳基苯甲酰胺衍生物
CN121159455A (zh) *	2024-06-18	2025-12-19	武汉人福创新药物研发中心有限公司	氨基酯类化合物及其作为p2x7拮抗剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0312609D0 (en) *	2003-06-02	2003-07-09	Astrazeneca Ab	Novel compounds
WO2006080884A1 (en) *	2005-01-27	2006-08-03	Astrazeneca Ab	Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7402596B2 (en) *	2005-03-24	2008-07-22	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en)	2005-04-11	2006-10-19	Abbott Laboratories	Acylhydrazide p2x7 antagonists and uses thereof

2009
- 2009-04-21 KR KR1020107026043A patent/KR101598397B1/ko not_active Expired - Fee Related
- 2009-04-21 CN CN2009801246595A patent/CN102066360B/zh not_active Expired - Fee Related
- 2009-04-21 JP JP2011506394A patent/JP5369173B2/ja not_active Expired - Fee Related
- 2009-04-21 ES ES09735472T patent/ES2376092T3/es active Active
- 2009-04-21 AT AT09735472T patent/ATE533762T1/de active
- 2009-04-21 AU AU2009239471A patent/AU2009239471B2/en not_active Ceased
- 2009-04-21 CA CA2722035A patent/CA2722035C/en not_active Expired - Fee Related
- 2009-04-21 WO PCT/US2009/041249 patent/WO2009132000A1/en not_active Ceased
- 2009-04-21 EP EP09735472A patent/EP2285800B1/de active Active
- 2009-04-21 US US12/988,891 patent/US8431704B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2009132000A1 (en)	2009-10-29
KR20110010732A (ko)	2011-02-07
CA2722035C (en)	2016-10-11
US20110092481A1 (en)	2011-04-21
ES2376092T3 (es)	2012-03-08
KR101598397B1 (ko)	2016-02-29
JP2011518226A (ja)	2011-06-23
CN102066360B (zh)	2013-10-30
EP2285800B1 (de)	2011-11-16
AU2009239471B2 (en)	2013-01-24
CN102066360A (zh)	2011-05-18
US8431704B2 (en)	2013-04-30
CA2722035A1 (en)	2009-10-29
AU2009239471A1 (en)	2009-10-29
JP5369173B2 (ja)	2013-12-18
EP2285800A1 (de)	2011-02-23

Publication	Publication Date	Title
ATE533762T1 (de)	2011-12-15	Chinolin- oder isochinolinsubstituierte p2x7- antagonisten
MY165113A (en)	2018-02-28	Piperidinone carboxamide azaindane cgrp receptor antagonists
CY1123365T1 (el)	2021-12-31	Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MX2012002179A (es)	2012-03-16	Compuestos heterociclicos de oxima.
UA107188C2 (uk)	2014-12-10	Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
MX2011009847A (es)	2011-09-29	Agentes antihelminticos y su uso.
BRPI1014902A2 (pt)	2016-04-19	composto antagonista de p2x7r, sua composição e seus usos
MX338114B (es)	2016-04-01	Inhibidores de arginasa y sus aplicaciones terapeuticas.
MY175272A (en)	2020-06-17	Novel benzimidazole derivatives as ep4 antagonists
ME01532B (me)	2014-04-20	Jedinjenja
UA112317C2 (uk)	2016-08-25	Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
NZ590650A (en)	2013-01-25	Buprenorphine analogs
BR112013021675A2 (pt)	2016-11-01	compostos de triazolopiridina como inibidores de pim cinase
MX2013012652A (es)	2014-05-27	Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
UA109290C2 (uk)	2015-08-10	Спільні кристали і солі інгібіторів ccr3
MX358307B (es)	2018-08-14	Formulaciones farmaceuticas que comprenden antagonistas de ccr3.
BR112014001908A2 (pt)	2017-02-21	derivados aza heterocíclicos substituídos
EA201400623A1 (ru)	2014-11-28	Новые 2h-индазолы в качестве антагонистов рецептора ep
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten
DE602007012313D1 (de)	2011-03-10	Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MX2011013869A (es)	2012-02-08	Agentes antihelminticos y su uso.
BRPI0818450A2 (pt)	2015-05-12	Antagonistas do receptor de 5-ht7
MA32224B1 (fr)	2011-04-01	Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
BR112014001714A2 (pt)	2017-02-14	derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
ATE525370T1 (de)	2011-10-15	Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten